TAIMED BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88 TWD | +0.92% |
|
+1.73% | +7.32% |
ETFs positioned on TaiMed Biologics Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 2 M€ | -.--% | ||
| 0.04% | 7 M€ | -.--% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +5.37% | - | |
| 0.00% | 34 M€ | +4.54% | - |
TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.
Calendar
2024-05-27
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
87.2
TWD
Average target price
133.7
TWD
Spread / Average Target
+53.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.32% | 738M | |
| +8.18% | 115B | |
| +12.65% | 107B | |
| -13.58% | 22.31B | |
| -3.99% | 21.6B | |
| -5.87% | 18.23B | |
| -39.93% | 17.62B | |
| +7.30% | 14.26B | |
| +33.59% | 12.37B | |
| -27.85% | 8.28B |
- Stock Market
- Equities
- 4147 Stock
- Funds and ETFs TaiMed Biologics Inc.